Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

COVID‐19 and Headache Medicine: A Narrative Review of Non‐Steroidal Anti‐Inflammatory Drug (NSAID) and Corticosteroid Use
Arca, Karissa N., Chiang, Chia‐Chun , Starling, Amaal J. , Robertson, Carrie E. , Schwedt, Todd J. , Kissoon, Narayan , Garza, Ivan , Rozen, Todd D. , Whealy, Mark , VanderPluym, Juliana H. , Chiang, Chia-Chun , Starling, Amaal J , Halker Singh, Rashmi B, Schwedt, Todd J , Kissoon, Narayan R , Garza, Ivan , Rozen, Todd D , Boes, Christoper J , Whealy, Mark A , Robertson, Carrie E , VanderPluym, Juliana , Smith, Jonathan H. , Singh, Rashmi B. Halker , Boes, Christopher J.

Mayo Clinic

Headache: The Journal of Head and Face Pain | July 10, 2020 | Volume: 60 | Issue: 8 | Pages: 1558-1568

10.1111/head.13903 | PMID 32648592 Get It

Objective To summarize the current literature on non‐steroidal anti‐inflammatory drug and corticosteroid use during the coronavirus disease 2019 (COVID‐19) pandemic, recognizing that these are commonly used treatments in the field of headache medicine. Background The use of non‐steroidal anti‐inflammatory drugs and corticosteroids in patients during the COVID‐19 pandemic has been a controversial topic within the medical community and international and national health organizations. Lay press and social media outlets have circulated opinions on this topic despite the fact that the evidence for or against the use of these medications is sparse. In the field of headache medicine, these medications are used commonly and both patients and clinicians may have questions or hesitations pertaining to their use during the COVID‐19 pandemic. Methods A detailed search of the scientific and popular literature was performed. Results There is limited literature pertaining to the safety of non‐steroidal anti‐inflammatory drugs and corticosteroids during the COVID‐19 pandemic. To date, there are no clear scientific data that preclude the use of non‐steroidal anti‐inflammatory drugs in the general population who may acquire COVID‐19 or in those acutely infected with the virus. Several health organizations have concluded that treatment with corticosteroids during active infection should be avoided due to concerns of prolonged viral shedding in the respiratory tract and the lack of survival benefit based on the data from past coronaviruses and influenza virus; specific exceptions exist including treatment for underlying asthma or chronic obstructive pulmonary disease, septic shock, and acute respiratory distress syndrome. Conclusion Scientific information regarding the COVID‐19 pandemic is constantly evolving, and limited or contradictory information can lead to confusion for both patients and clinicians. It is recommended that prior to prescribing non‐steroidal anti‐inflammatory drugs and steroids for the treatment of headache, clinicians have open discussions with their patients about the potential risks and benefits of using these medications during the COVID‐19 pandemic. This manuscript summarizes the currently available evidence and understanding about these risks and benefits to help clinicians navigate such discussions.
Cardiopulmonary Considerations for High School Student-Athletes During the COVID-19 Pandemic: NFHS-AMSSM Guidance Statement
Heinz, William M., Asif, Irfan M. , Batten, Casey G., Fields, Karl B., Valentine, Verle, Walter, Kevin D., Raukar, Neha P. , Drezner, Jonathan A. , Batten, Casey G.

Mayo Clinic

Sports Health: A Multidisciplinary Approach | July 9, 2020 | Volume: 12 | Issue: 5 | Pages: 459-461

10.1177/1941738120941490 | PMID 32640879 Get It

The Influence Of Physical Activity And Body Composition On Gene Expression In Breast Adipose Tissue
Schulte, Hannah K., Neil‐Sztramko, Sarah , Nyamundanda, Gift, Bland, K I, Campbell, Kristin L. , Neil-Sztramko, Sarah , Kannan, Nagarajan , Sadanandam, Anguraj , Little, Jonathan P. , Johnson, James D. , Csizmadi, Ilona , Bland, Kelcey A.

Mayo Clinic

Medicine & Science in Sports & Exercise | July 9, 2020 | Volume: 52 | Issue: 7S | Pages: 984-984

10.1249/01.mss.0000686272.19701.5b Get It

Circulating Protein Biomarkers in Rheumatoid Arthritis Associated Interstitial Lung Disease
Cardwell, Jonathan, Yang, I.V. , Matteson, E. L., Lee, J.S., Matson, Scott M. , Deane, Kevin D , Ryu, Jay H. , Wolters, Paul J. , Schwartz, David A.

Mayo Clinic

A23. ILD PROGNOSIS AND BIOMARKERS I | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A1094-A1094

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1094 Get It

A Follow-On Prospective Clinical Validation of the Envisia Genomic Classifier
Scholand, Mary Beth , Nathan, Steven D. , Colby, Thomas V. , Groshong, Steve D. , Lynch, David A. , Lancaster, Lisa , Oldham, Justin, Patel, nbspHemal, Choi, Y. , Pankrantz, D., Bhorade, Sangeeta , Lofaro, Lori , Huang, Jing , Raghu, Ganesh , Chung, Jonathan Hero , Patel, N., Kennedy, G.

Mayo Clinic

A102. ILD DIAGNOSIS AND MONITORING | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A2557-A2557

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2557 Get It

Artificial Intelligence and Machine Learning in Arrhythmias and Cardiac Electrophysiology
Feeny, Albert , Chung, Mina K. , Attia, Zachi I. , Čikeš, Maja , Firouznia, Marjan , Friedman, Paul A. , Kalscheur, Matthew M. , Narayan, Sanjiv M. , Piccini, Jonathan P. , Tarakji, Khaldoun G. , Thomas, Suma A., Turakhia, Mintu P. , Wang, Paul J. , Attia, Zachi I , Kalscheur, Matthew M , Turakhia, Mintu P , Narayan, Sanjiv M , Madabhushi, Anant , Kapa, Suraj , Noseworthy, Peter A. , Passman, Rod , Pérez, Marco , Peters, Nicholas Simon , Trayanova, Natalia A.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 6, 2020 | Volume: 13 | Issue: 8 | Pages: No page available

10.1161/circep.119.007952 | PMID 32628863 Get It

Artificial intelligence (AI) and machine learning (ML) in medicine are currently areas of intense exploration, showing potential to automate human tasks and even perform tasks beyond human capabilities. Literacy and understanding of AI/ML methods are becoming increasingly important to researchers and clinicians. The first objective of this review is to provide the novice reader with literacy of AI/ML methods and provide a foundation for how one might conduct an ML study. We provide a technical overview of some of the most commonly used terms, techniques, and challenges in AI/ML studies, with reference to recent studies in cardiac electrophysiology to illustrate key points. The second objective of this review is to use examples from recent literature to discuss how AI and ML are changing clinical practice and research in cardiac electrophysiology, with emphasis on disease detection and diagnosis, prediction of patient outcomes, and novel characterization of disease. The final objective is to highlight important considerations and challenges for appropriate validation, adoption, and deployment of AI technologies into clinical practice.
Variation in Fluid and Vasopressor Use in Shock With and Without Physiologic Assessment: A Multicenter Observational Study
Chen, Jen‐Ting , Roberts, Russel J. , Qadir, Nida , Cairns, Charles B. , Mathews, Kusum S. , Park, Pauline, Khan, Akram , Gilmore, James F. , Brown, Anne Rain , Tsuei, Betty J., Handzel, Michele, Chang, Alfredo Lee, Herbert, James T. , Martinez, Anthony , Tonna, Joseph E. , Nazer, Lama , Heavner, Mojdeh S. , Pender, Erin, Chambers, Lauren, Kenes, Michael T. , Kaufman, David A. , Downey, April, Chaykosky, Darlene, Wolff, Armand, Smith, Michael , Nault, Katie, Sevransky, Jonathan, Gong, Michelle N. , Network, on behalf of the VOLUME-CHASERS Study Group and Society of Critical Care Medicine Discovery, Tonna, Joseph E. , Heavner, Mojdeh S , Khan, Akram , Fazzari, Melissa J. , Kashani, Kianoush , Park, Pauline K. , Duggal, Abhijit , Lanspa, Michael J. , Ammar, Mahmoud A , Hammond, Drayton A , Brown, Brent , Network, on behalf of the VOLUME-CHASERS Study Group and Society of Critical Care Medicine Discovery

Mayo Clinic

Critical Care Medicine | June 30, 2020 | Volume: 48 | Issue: 10 | Pages: 1436-1444

10.1097/ccm.0000000000004429 | PMID 32618697 Get It

Objectives: To characterize the association between the use of physiologic assessment (central venous pressure, pulmonary artery occlusion pressure, stroke volume variation, pulse pressure variation, passive leg raise test, and critical care ultrasound) with fluid and vasopressor administration 24 hours after shock onset and with in-hospital mortality. Design: Multicenter prospective cohort study between September 2017 and February 2018. Settings: Thirty-four hospitals in the United States and Jordan. Patients: Consecutive adult patients requiring admission to the ICU with systolic blood pressure less than or equal to 90 mm Hg, mean arterial blood pressure less than or equal to 65 mm Hg, or need for vasopressor. Interventions: None. Measurement and Main Results: Of 1,639 patients enrolled, 39% had physiologic assessments. Use of physiologic assessment was not associated with cumulative fluid administered within 24 hours of shock onset, after accounting for baseline characteristics, etiology and location of shock, ICU types, Acute Physiology and Chronic Health Evaluation III, and hospital (beta coefficient, 0.04; 95% CI, −0.07 to 0.15). In multivariate analysis, the use of physiologic assessment was associated with a higher likelihood of vasopressor use (adjusted odds ratio, 1.98; 95% CI, 1.45−2.71) and higher 24-hour cumulative vasopressor dosing as norepinephrine equivalent (beta coefficient, 0.37; 95% CI, 0.19−0.55). The use of vasopressor was associated with increased odds of in-hospital mortality (adjusted odds ratio, 1.88; 95% CI, 1.27−2.78). In-hospital mortality was not associated with the use of physiologic assessment (adjusted odds ratio, 0.86; 95% CI, 0.63−1.18). Conclusions: The use of physiologic assessment in the 24 hours after shock onset is associated with increased use of vasopressor but not with fluid administration.
Longitudinal clinical, neuropsychological, and neuroimaging characterization of a kindred with a 12-octapeptide repeat insertion in PRNP: the next generation
Townley, Ryan , Polsinelli, Angelina J. , Fields, Julie A. , Graff‐Radford, Jonathan , Kantarci, Kejal , Lowe, Val J. , Rademakers, Rosa , Baker, Matt , Kumar, Neeraj , Townley, Ryan A , Kantarci, Kejal M, Rademakers, Rosa V, Baker, Matt C, Kantarci, Kejal , Machulda, Mary M. , Jones, David T. , Boeve, Bradley F.

Mayo Clinic

Neurocase | June 30, 2020 | Volume: 26 | Issue: 4 | Pages: 211-219

10.1080/13554794.2020.1787458 | PMID 32602775 Get It

Patterns of oral anticoagulation use with cardioversion in clinical practice
Geurink, Kyle R. , Holmes, DaJuanicia N. , Ezekowitz, Michael D. , Pieper, Karen S. , Kowey, Peter R. , Reiffel, James A. , Singer, Daniel E. , Mahaffey, Kenneth W. , Piccini, Jonathan P. , Geurink, Kyle , Piccini, Jonathan P , Fonarow, Gregg C. , Freeman, James V. , Gersh, Bernard J. , Hylek, Elaine M. , Naccarelli, Gerald V. , Peterson, Eric D. , Pokorney, Sean D.

Mayo Clinic

Heart | June 26, 2020 | Volume: 107 | Issue: 8 | Pages: 642-649

10.1136/heartjnl-2019-316315 | PMID 32591363 Get It

Background Cardioversion is common among patients with atrial fibrillation (AF). We hypothesised that novel oral anticoagulants (NOAC) used in clinical practice resulted in similar rates of stroke compared with vitamin K antagonists (VKA) for cardioversion. Methods Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II, patients with AF who had a cardioversion, follow-up data and an AF diagnosis within 6 months of enrolment were identified retrospectively. Clinical outcomes were compared for patients receiving a NOAC or VKA for 1 year following cardioversion. Results Among 13 004 patients with AF, 2260 (17%) underwent cardioversion. 1613 met the inclusion criteria for this analysis. At the time of cardioversion, 283 (17.5%) were receiving a VKA and 1330 (82.5%) a NOAC. A transoesophageal echocardiogram (TOE) was performed in 403 (25%) cardioversions. The incidence of stroke/transient ischaemic attack (TIA) at 30 days was the same for patients having (3.04 per 100 patient-years) or not having (3.04 per 100 patient-years) a TOE (p=0.99). There were no differences in the incidence of death (HR 1.19, 95% CI 0.62 to 2.28, p=0.61), cardiovascular hospitalisation (HR 1.02, 95% CI 0.76 to 1.35, p=0.91), stroke/TIA (HR 1.18, 95% CI 0.30 to 4.74, p=0.81) or bleeding-related hospitalisation (HR 1.29, 95% CI 0.66 to 2.52, p=0.45) at 1 year for patients treated with either a NOAC or VKA. Conclusions Cardioversion was a low-risk procedure for patients treated with NOAC, and there were statistically similar rates of stroke/TIA 30 days after cardioversion as for patients treated with VKA. There were no statically significant differences in death, stroke/TIA or major bleeding at 1 year among patients treated with NOAC compared with VKA after cardioversion.
The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer
Epstein, Jonathan I. , Amin, Mahul B. , Fine, Samson W. , Algaba, Ferrán, Aron, Manju , Baydar, Dilek Ertoy , Brimo, Fadi , Cheville, John C. , Colecchia, Maurizio , Cunha, Isabela Werneck da , Delprado, Warick, Giannico, Giovanna A. , Gordetsky, Jennifer , Hansel, Donna E. , Hirsch, Michelle S. , Huang, Jiaoti , Humphrey, Peter A. , Jiménez, Rafael E. , Khani, Francesca , Kong, Qingnuan , Kunju, Lakshmi P., Lal, Priti , Latour, Mathieu, Lotan, Tamara, Mehra, Rohit , Miyamoto, Hiroshi , Montironi, Rodolfo , Netto, George J. , Nguyen, Jane , Osunkoya, Adeboye O. , Robinson, Brian D. , Rubin, Mark A. , So, Jeffrey , Takahashi, Hiroyuki , Tavora, Fabio, Tretiakova, Maria , True, Lawrence D. , Wobker, Sara E. , Yang, Ximing J. , Zhou, Ming , Zynger, Debra L. , Trpkov, Kiril , Távora, Fábio , Gordetsky, Jennifer B , Tretiakova, Maria S , Robinson, Brian D. , Rubin, Mark A , Trpkov, Kiril , López-Beltrán, Antonio , Compérat, Éva , Marzo, Angelo M. De , Guo, Charles Chuanhai , Kryvenko, Oleksandr N. , Maclean, Fiona M. , Magi‐Galluzzi, Cristina , Menon, Santosh , Parwani, Anil Vasdev , Shah, Rajal B.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | June 26, 2020 | Volume: 145 | Issue: 4 | Pages: 461-493

10.5858/arpa.2020-0015-ra | PMID 32589068 Get It

Context.— Controversies and uncertainty persist in prostate cancer grading. Objective.— To update grading recommendations. Data Sources.— Critical review of the literature along with pathology and clinician surveys. Conclusions.— Percent Gleason pattern 4 (%GP4) is as follows: (1) report %GP4 in needle biopsy with Grade Groups (GrGp) 2 and 3, and in needle biopsy on other parts (jars) of lower grade in cases with at least 1 part showing Gleason score (GS) 4 + 4 = 8; and (2) report %GP4: less than 5% or less than 10% and 10% increments thereafter. Tertiary grade patterns are as follows: (1) replace “tertiary grade pattern” in radical prostatectomy (RP) with “minor tertiary pattern 5 (TP5),” and only use in RP with GrGp 2 or 3 with less than 5% Gleason pattern 5; and (2) minor TP5 is noted along with the GS, with the GrGp based on the GS. Global score and magnetic resonance imaging (MRI)-targeted biopsies are as follows: (1) when multiple undesignated cores are taken from a single MRI-targeted lesion, an overall grade for that lesion is given as if all the involved cores were one long core; and (2) if providing a global score, when different scores are found in the standard and the MRI-targeted biopsy, give a single global score (factoring both the systematic standard and the MRI-targeted positive cores). Grade Groups are as follows: (1) Grade Groups (GrGp) is the terminology adopted by major world organizations; and (2) retain GS 3 + 5 = 8 in GrGp 4. Cribriform carcinoma is as follows: (1) report the presence or absence of cribriform glands in biopsy and RP with Gleason pattern 4 carcinoma. Intraductal carcinoma (IDC-P) is as follows: (1) report IDC-P in biopsy and RP; (2) use criteria based on dense cribriform glands (>50% of the gland is composed of epithelium relative to luminal spaces) and/or solid nests and/or marked pleomorphism/necrosis; (3) it is not necessary to perform basal cell immunostains on biopsy and RP to identify IDC-P if the results would not change the overall (highest) GS/GrGp part per case; (4) do not include IDC-P in determining the final GS/GrGp on biopsy and/or RP; and (5) “atypical intraductal proliferation (AIP)” is preferred for an intraductal proliferation of prostatic secretory cells which shows a greater degree of architectural complexity and/or cytological atypia than typical high-grade prostatic intraepithelial neoplasia, yet falling short of the strict diagnostic threshold for IDC-P. Molecular testing is as follows: (1) Ki67 is not ready for routine clinical use; (2) additional studies of active surveillance cohorts are needed to establish the utility of PTEN in this setting; and (3) dedicated studies of RNA-based assays in active surveillance populations are needed to substantiate the utility of these expensive tests in this setting. Artificial intelligence and novel grading schema are as follows: (1) incorporating reactive stromal grade, percent GP4, minor tertiary GP5, and cribriform/intraductal carcinoma are not ready for adoption in current practice.